Avacta Group
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms—Affimer® biotherapeutics and pre|CISION™ tumor targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The company’s therapeutics development activities are based in Cambridge, UK.
Content by Avacta Group
|2 min read
Avacta Launches SARS-CoV-2 BAMS Research Test
Affimer-based research assay launched alongside performance data published by Bruker
|2 min read
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus
Page 1 of 1
